A class-action suit alleges St. Louis health giant Ascension shared private patient records with Google, claiming violations of federal privacy rules and seeking class relief.

Cincinnati Childrens won a five‑year, up‑to‑$17.25M ARIA award to join the IMPACT Network and begin local enrollment for a study meant to speed autism trials.

Microsoft CEO Satya Nadella warned that a handful of dominant AI systems could “hollow out entire industries,” urging firms to build private learning loops to protect jobs and IP.

A multilayered security buildout uses AI cameras and counter‑drone gear to guard matches and fan zones in Miami. Officials say the tech flags threats in real time while agencies enforce no‑drone rules.

UH Mānoa researchers published the first live, in‑situ footage of goblin sharks, documenting Central Pacific sightings that extend the species’ depth and range.

Pitt researchers turned a harmless eye bacterium into a prototype "living eye drop" that secretes anti-inflammatory IL-10 and sped cornea healing in mice. The proof-of-concept could reduce repeated dosing, but human trials are still distant.

Ángel Cabrera will step down as Georgia Tech president this November to lead the Aspen Institute; he will remain through the holidays to oversee the transition.

Nvidia plans to sell at least $20 billion of bonds in a seven‑part offering to refinance debt and fund AI investments.

UCSF researchers describe an implanted adaptive DBS system that times stimulation to walking and reduced falls in a small Parkinson's feasibility trial.

UC San Diego and Stanford researchers found brief electrical pulses rejuvenated sea squirts and raised questions about stem‑cell aging in people.

UT Austin and MD Anderson launched a cross‑campus accelerator funding five projects to speed protein therapies, AI and surgical robotics into patient care.

Phoenix is expanding apprenticeships into biomanufacturing to train residents for GLP‑1 drug production, turning regional biotech demand into local job pathways.

Nano Dimension signed a non‑binding term sheet to merge with Infinite Epigenetics in a proposed $890M stock deal that would pivot the Waltham company into AI‑powered health diagnostics. The combined firm would seek the Nasdaq ticker IEAI and access to more than $400M in cash at closing.